Navigation Links
Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
Date:2/8/2012

ALISO VIEJO, Calif., Feb. 8, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that the results of the study entitled "Efficacy and Safety of Dextromethorphan/Quinidine (AVP-923) at Two Dosage Levels for Diabetic Neuropathic Pain: A Double-Blind, Placebo-Controlled, Multicenter Study" have been published in the February edition of the journal Pain Medicine.

"Throughout a 13-week trial, AVP-923 was effective, with an acceptable safety profile, for treatment of diabetic peripheral neuropathic pain. The findings indicate that other fixed-dose combinations of AVP-923 should be studied to improve overall tolerability while maintaining significant efficacy," said Aziz Shabaini, MD, Medical Director of the Nerve and Muscle Center, Texas.

AVP-923 is a combination of dextromethorphan (DM) and quinidine (Q). AVP-923 is currently being studied in a Phase II clinical trial (the PRIME study) in central neuropathic pain in patients with multiple sclerosis.

"Today's publication in a leading peer-review medical journal complements a body of scientific literature suggesting that dextromethorphan could be efficacious in neuropathic pain," said Joao Siffert, MD, senior vice president of research and development at Avanir. "These results provide additional rationale in support of the ongoing PRIME study, which is evaluating the combination of dextromethorphan and quinidine in central neuropathic pain in patients with multiple sclerosis."

Study Design

In a 13-week, phase III, randomized, controlled trial, 379 adults with daily symmetric diabetic peripheral neuropathy (DPN) leg pain for >3 months received double-blind placebo, DMQ 45/30 mg, or DMQ 30/30 mg, administered once daily for 7 days and twice daily thereafter. Efficacy measures included four pain rating scales applied daily using patient diaries, and anoth
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
2. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
3. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
4. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
5. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
6. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
7. Avanir Pharmaceuticals to Participate in Two Investor Conferences
8. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
9. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
10. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
11. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... , Spanje, July 4, 2015 ... harsmicrosferen aan eerstelijns chemotherapie voor patiënten met ... (mCRC) verlengt de progressievrije overleving in dat ... gemetastaseerde colorectale kanker (mCRC) die alleen binnen ... gezien in progressievrije overleving (PFS) in de ...
(Date:7/3/2015)... July 4, 2015 A global ... hypertension, diabetes and thyroid disorders in Central and ... platforms and a major conference dedicated to these diseases. ... Manage Diabetes Online , Manage Hypertension Online ... and operated by EXCEMED - combine the ...
(Date:7/3/2015)... A global continuing medical education ... thyroid disorders in Latin America ... dedicated to these diseases.      (Logo: http://photos.prnewswire.com/prnh/20150630/227033) ... Manage Hypertension Online and Manage Thyroid Online ... - combine the world,s top expertise with dynamic ...
Breaking Medicine Technology:Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5Combating Three Major Chronic Diseases in Central and South-East Asia With Medical Education 2Combating Three Major Chronic Diseases in Latin America With Medical Education 2
... announces that a new market research report is available ... Discoveries: what the future holds ... Original analysis of the clinical potential and commercial prospects ... current market context Original analysis of the ...
... 2011 Reportlinker.com announces that a new market ... Levosimendan - Comprehensive patent search ... Eliminate unnecessary risk with the industry benchmark in ... a regularly updated, professional patent search performed by ...
Cached Medicine Technology:Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 2Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 3Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 4Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 5Reportlinker Adds Levosimendan - Comprehensive patent search 2Reportlinker Adds Levosimendan - Comprehensive patent search 3Reportlinker Adds Levosimendan - Comprehensive patent search 4
(Date:7/3/2015)... ... July 03, 2015 , ... ... speaker lineup for its 2015 Annual Conference , the premiere continuing ... at the Renaissance Orlando at SeaWorld in Orlando, Florida. Speakers include the ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. ... been retained to lead a national president recruitment for Regional Care, ... healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
(Date:7/3/2015)... ... ... Smoothies are all the rage right now and all you need to ... Natural is proud to introduce a new line of all natural products that blend ... minerals! , Aurora is offering a variety of blends and stand-alone items to choose ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency Room ... Mariah N. Manzanares, MD as the new Medical Director of its Frisco facility. , ... of our Frisco facility,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:7/3/2015)... Alberta (PRWEB) , ... July 03, 2015 , ... Every ... their 24-Hour Train-a-Thon where they provide members of the Red Deer community with free ... full day of fitness training, games, food, events and entertainment raised thousands of charity ...
Breaking Medicine News(10 mins):Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: